D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reissued by D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They currently have a $15.00 target price on the stock. D. Boral Capital’s price objective indicates a potential upside of 173.22% from the company’s current price.

A number of other research firms also recently weighed in on COYA. Chardan Capital restated a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, November 11th.

Coya Therapeutics Stock Performance

Shares of NASDAQ:COYA traded up $0.11 on Tuesday, hitting $5.49. The company’s stock had a trading volume of 6,821 shares, compared to its average volume of 59,403. Coya Therapeutics has a 12 month low of $4.75 and a 12 month high of $10.69. The stock’s 50-day moving average is $5.98 and its two-hundred day moving average is $6.48. The company has a market capitalization of $91.74 million, a price-to-earnings ratio of -8.45 and a beta of 0.46.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.15. Equities analysts expect that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Insider Buying and Selling at Coya Therapeutics

In other news, CEO Arun Swaminathan acquired 5,000 shares of Coya Therapeutics stock in a transaction on Monday, November 11th. The stock was bought at an average cost of $7.34 per share, with a total value of $36,700.00. Following the completion of the purchase, the chief executive officer now owns 5,000 shares of the company’s stock, valued at $36,700. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last 90 days, insiders have purchased 9,510 shares of company stock valued at $69,615. Corporate insiders own 9.80% of the company’s stock.

Institutional Investors Weigh In On Coya Therapeutics

A number of large investors have recently made changes to their positions in the company. Renaissance Technologies LLC bought a new stake in Coya Therapeutics during the second quarter worth approximately $101,000. GHP Investment Advisors Inc. acquired a new stake in Coya Therapeutics in the 3rd quarter valued at approximately $169,000. Finally, Geode Capital Management LLC raised its stake in Coya Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after purchasing an additional 4,485 shares during the last quarter. Institutional investors and hedge funds own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.